Navigation Links
VIVUS Provides Regulatory Update on QNEXA NDA
Date:1/21/2011

MOUNTAIN VIEW, Calif., Jan. 21, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it held an End-of-Review meeting with the Food and Drug Administration (FDA) for the New Drug Application (NDA) for QNEXA®, an investigational drug for the treatment of obesity.  The meeting occurred on January 19th at the FDA's offices in Maryland and was attended by senior members of the FDA and VIVUS' management and consultants.  At this meeting the FDA requested that VIVUS assess the feasibility of analyzing existing healthcare databases to determine the historical incidence of oral cleft in offspring of women treated with topiramate for migraine prophylaxis (100 mg).

Based on discussions at the meeting, VIVUS believes the FDA's additional request stems from two published reports which cited two oral clefts in the UK Epilepsy and Pregnancy Register (Hunt et al., July 2008) and four, including two isolated cleft lips, from the North American AED Pregnancy Registry (Hernandez-Diaz et al., June 2010).  In the QNEXA® studies, which included 15 births from women exposed to QNEXA® or topiramate, there were no reports of any fetal malformations. The timing of the planned resubmission of the QNEXA® NDA will be determined after agreement with the FDA is reached on the feasibility assessment.  VIVUS anticipates continued dialog with the FDA on the planned resubmission of the QNEXA® NDA.

About QNEXA® Controlled Release Capsules QNEXA® [kyoo-nek-suh] is an investigational drug being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA® is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which together decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
2. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
3. VIVUS to Present at Two Upcoming Investor Conferences
4. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
5. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
6. VIVUS Announces Sale of MUSE Assets to Meda
7. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
8. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
9. VIVUS to Present at Lazard Capital Markets Healthcare Conference
10. VIVUS Announces Promotion of Peter Tam to President
11. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
(Date:7/10/2014)... 2014  Breg, Inc., a premier provider of ... FreeRunner™ knee brace with new innovations to help ... return to active lifestyles.  FreeRunner,s patent-pending design acts ... support when patients need it most, and the ... Patellofemoral issues are the most common cause ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... privately-held therapeutic device company, today announced that DEKRA and Health ... Matrix for clinical use and sale in Europe and Canada. ... resistant, and absorbable putty designed to rapidly stop bleeding when ... cut bone is a problem in many operative procedures including ...
... announces that a new market research report is available ... Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html ... Summary GlobalData,s "Medical Equipment ... of data and trend analysis on mergers and acquisitions ...
Cached Medicine Technology:ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB® 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 2Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 3Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 4Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 5Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 6Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 7Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 8Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 9Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 10Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 11Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 12Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 13Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 14Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 15Reportlinker Adds Medical Equipment Annual Deals Analysis 2011 16
(Date:7/14/2014)... 14, 2014 EnergyFirst, manufacturer ... company Permalean for its great products, thriving ... Permalean, which markets its products as Jim’s Permalean Protein ... part of EnergyFirst’s lineup of nutritional products. The ... the coming year. , Founded in 1999, Permalean’s products ...
(Date:7/14/2014)... New research and analysis from the national ... examines toxic ingredients in tampons, a product used ... chemicals that may be found in the product’s absorptive ... put women’s health at risk. , According to ... , the potential impact of toxic chemical exposure from ...
(Date:7/13/2014)... FORT LEE, N.J. – Authors Leonard I. ... the science of tooth implants in their book ... describes recent advances and techniques in the world of dentistry ... who have lost all of their natural teeth. , Dr. ... subperiosteal implant in 1940. It was a mesh frame ...
(Date:7/13/2014)... 2014 MED-Ed Facilities is seeking proposals ... conference, April 7+8 in Boston at the Seaport Hotel. ... recent event. Presentations by individuals or teams are welcome. ... the types of sessions that were presented last year, ... proposal today! , Conference Director, The successful planning ...
(Date:7/13/2014)... Worldwide ladies are extremely responsive to Angeldress.co.uk’s pink ... approach and has created a lot of new items ... choices that responded directly to customers’ demands. , ... apparels. The company’s pink bridesmaid dresses come in many ... create the best products for customers from around the ...
Breaking Medicine News(10 mins):Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 2Health News:EnergyFirst Acquires Permalean - Manufacturer of All Natural Protein Bars and Powders 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:MED-Ed Facilities Conference Call for Speakers Open 2Health News:Angeldress.co.uk Announces Summer Sale For Pink And Red Bridesmaid Dresses; The Current Discount Is Up To 80% Off 2
... you think. Low doses of radiation have been found to ... not uncommon for children who suffer from medulloblastoma to undergo ... in affecting IQ and reading skills of younger children rather ... has been found that the greatest rates of decline in ...
... has claimed at least 20 lives in the past two ... is already present in the neighboring Indian state of UP ... caused 10 deaths each in the townships of Tikapur and ... over 80 patients were undergoing treatment in various hospitals and ...
... that the loss of a gene called p63 accelerates the ... present in many organisms, including humans // . Drawing parallels ... is likely to play a fundamental biological role in aging-related ... researchers had devised a system for eliminating it from adult ...
... prevent infections in older people living at home, report ... segment of the supplement-taking population. //, ,Studies in ... supplements, elderly people in nursing homes were 20 per ... had fewer colds over the study period than a ...
... at Jefferson Medical College had discovered the existence of ... biomarker for conditions that lead to heart failures. Based ... a blood test to predict the onset of heart ... previously showed that an enzyme called GRK2 or beta-adrenergic ...
... become nearly twice as prevalent in high schools in the ... middle school students admit that drugs are used, kept or ... where drugs are widely available are three times more likely ... alcohol than their peers who attend drug-free schools., ,Availability ...
Cached Medicine News:Health News:Latest Research Shows That Multivitamins Might Not Prevent Infections In All Elderly 2Health News:Blood Test To Predict Heart Failures 2
... complete line of enteric disease ... and monoclonal/polyclonal antibody-based ELISA tests ... pathogens in fecal specimens. Our ... difficile, Entamoeba histolytica, Giardia, Cryptosporidium ...
... II test is also available with Inverness ... greatly reduces the hands-on time required to ... testing. The Fecal-Quik-Prep device is a unique ... amount of hands-on time required to prepare ...
... for autoimmune testing feature single-well ANA screen ... specific reflex tests including dsDNA, and 6 ... SS-B (La), Scl-70 and Jo-1. In addition, ... line of products for Cardiolipins (IgA, IgG, ...
... Our ELISA products for autoimmune testing ... ELISAs, as well as specific reflex tests ... Sm, Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 ... family includes a full line of products ...
Medicine Products: